28 April 2020 - Data show more than half of trial patients across all 10 tumour types studied had responses to treatment, including in patients where cancer has spread to the central nervous system.

Roche Canada is pleased to announce that on 10 February 2020, Health Canada, under the Notice of Compliance with Conditions (NOC/c) policy, approved Rozlytrek (entrectinib) for adult patients with unresectable locally advanced or metastatic extra-cranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.

Rozlytrek is Roche's first tumour-agnostic treatment which works by targeting the underlying gene mutation (NTRK) which is responsible for driving oncogenesis or the growth of cancer cells in tumours.

Read Roche press release